Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"DeepCure","sponsor":"IAG Capital Partners","pharmaFlowCategory":"D","amount":"$24.6 million","upfrontCash":"Undisclosed","newsHeadline":"DeepCure Closes $24M Funding Round Led by IAG Capital Partners","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by DeepCure

    Menu

    DeepCure

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              DeepCure

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DeepCure Closes $24M Funding Round Led by IAG Capital Partners

              Details:

              The net proceeds will be used to further develop DeepCure’s cutting-edge technology for small molecule drug discovery, and to advance its immunology and inflammation pipeline towards clinical trials.

              Lead Product(s): Brd4

              Therapeutic Area: Immunology Product Name: Brd4

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: IAG Capital Partners

              Deal Size: $24.6 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing April 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY